好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

The Frequency of Optic Disc Hemorrhages and Other Retinal Findings on Fundoscopic Examination in Acute MOGAD Optic Neuritis
Autoimmune Neurology
P11 - Poster Session 11 (8:00 AM-9:00 AM)
8-005

To determine the fundoscopic findings in acute optic neuritis (ON) from myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) and their association with visual outcomes

ON is the most common presentation of MOGAD and is often associated with optic disc edema (ODE) and occasionally other retinal findings, but their frequency and clinical implications have not been systematically explored.

A retrospective chart review of patients evaluated at Mayo Clinic between 1/1/00-2/28/24 and fulfilling the 2023 international MOGAD criteria was performed. Patients with fundoscopic examination within 2 weeks of the first ON attack and follow-up ≥3 months after the attack were included. Only the first or more severely affected eye was included for each patient.

A total of 106 MOGAD patients were included, 50 with bilateral ON. The median age at attack onset was 37 (IQR 22-52) years, with 23% pediatric, 68% female, and 96% White. ODE was present in 88 (81%), with 23/82 (22%) having severe edema. Optic disc hemorrhage was observed in 15 (14%) patients, 14 with concurrent severe ODE and 1 with moderate ODE. Four (4%) patients had additional retinal findings, 3 with concomitant moderate-severe ODE. One patient had ODE and macular star consistent with neuroretinitis, one had scattered hemorrhages with engorged veins consistent with venous stasis retinopathy, one had dilated veins, and one had peripheral retinal hemorrhages. The median Snellen visual acuity (VA) at nadir was 20/200 (IQR 20/30-hand motion), and 86/103 (83%) fully recovered to VA 20/20. Optic disc hemorrhage or retinal findings were not associated with statistically worse VA at nadir or follow-up.

Optic disc hemorrhages and other retinal findings were observed in 16% of acute MOGAD-ON attacks, which were often accompanied by ODE. Given the low rate of residual VA deficits, the association between these findings and outcomes was inconclusive.

Authors/Disclosures
Nanthaya Tisavipat, MD (Mayo Clinic)
PRESENTER
Miss Tisavipat has nothing to disclose.
Natthapon Rattanathamsakul, MD (Mayo Clinic) Dr. Rattanathamsakul has nothing to disclose.
Mary Lang Ms. Lang has received intellectual property interests from a discovery or technology relating to health care.
Grant Welk, BS Mr. Welk has nothing to disclose.
Deena Tajfirouz, MD Dr. Tajfirouz has nothing to disclose.
Kevin Chodnicki (Mayo Clinic) Kevin Chodnicki has nothing to disclose.
Sean J. Pittock, MD, FAAN (Mayo Clinic Dept of Neurology) Dr. Pittock has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Arialys. The institution of Dr. Pittock has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. The institution of Dr. Pittock has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. The institution of Dr. Pittock has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche/Genentech. The institution of Dr. Pittock has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Alexion/AstraZeneka. The institution of Dr. Pittock has received research support from NIH. Dr. Pittock has received intellectual property interests from a discovery or technology relating to health care. Dr. Pittock has received intellectual property interests from a discovery or technology relating to health care. Dr. Pittock has received publishing royalties from a publication relating to health care.
Eoin P. Flanagan, MBBCh, FAAN (Mayo Clinic) The institution of Dr. Flanagan has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Flanagan has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Pharmacy times. The institution of Dr. Flanagan has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for UCB. The institution of Dr. Flanagan has received research support from UCB. The institution of Dr. Flanagan has received research support from Roche. The institution of Dr. Flanagan has received research support from UCB. The institution of Dr. Flanagan has received research support from Merck. The institution of Dr. Flanagan has received research support from Roche. Dr. Flanagan has received publishing royalties from a publication relating to health care. Dr. Flanagan has received publishing royalties from a publication relating to health care. Dr. Flanagan has a non-compensated relationship as a Member of medical Advisory Board with The MOG Project that is relevant to AAN interests or activities. Dr. Flanagan has a non-compensated relationship as a Editorial board member with Journal of The Neurologic Sciences that is relevant to AAN interests or activities. Dr. Flanagan has a non-compensated relationship as a Editorial board member with Neuroimmunology Reports that is relevant to AAN interests or activities. Dr. Flanagan has a non-compensated relationship as a Editorial Board Member with Neurology, Neuroimmunology Neuroinflammation (N2) Journal that is relevant to AAN interests or activities. Dr. Flanagan has a non-compensated relationship as a Editorial Board Member with Neurology that is relevant to AAN interests or activities.
John Chen John Chen has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for UCB. John Chen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amgen. John Chen has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for UCB.